Zanzalintinib FDA Delay Pushes CRC Decision to March 2027, Adding Regulatory Uncertainty

What happened

Exelixis disclosed a three-month FDA review delay for its zanzalintinib colorectal cancer application, moving the potential decision from late 2026 to March 2027. This comes despite positive Phase 3 STELLAR-303 overall survival data and management's prior expectation of a late-2026 approval. The delay adds to an already uncertain regulatory path that includes endpoint-change scrutiny and binary risk, while 2026 financial guidance excludes any zanzalintinib revenue. Cabometyx remains the sole commercial engine, and its composition-of-matter patent expires in 2026, increasing reliance on pipeline execution. Investors should treat the news as a modest negative that extends the timeline to diversification and pressures the stock's premium valuation.

Implication

For current holders, the three-month delay does not break the investment thesis but chips away at the bull case, as zanzalintinib revenue remains outside 2026 guidance and now arrives later, weakening the near-term optionality that investors have been pricing in. The stock's roughly 17x forward earnings valuation already embeds some pipeline hope, so the margin of safety narrows further; we would trim into strength above $52 and only consider adding on a pullback toward $38, consistent with our prior framework. Cabometyx prescription share trends and the STELLAR-304 non-clear-cell RCC data in the first half of 2026 remain the key near-term catalysts, and any additional regulatory slippage or weakening in Cabometyx growth would justify a more defensive posture. Until then, a WAIT rating with reduced conviction (2.0) is appropriate, focusing on execution metrics rather than zanzalintinib optionality. The delay also shifts the bear scenario probability modestly higher, as the company now has a longer window of single-product dependence before any potential second franchise contributes.

Thesis delta

The FDA delay for zanzalintinib moves the CRC decision from late 2026 to March 2027, extending the timeline for a second commercial franchise and reducing the probability-weighted value of near-term pipeline optionality. With Cabometyx still the sole revenue driver and its patent cliff starting in 2026, the investment case skews more bearish until clearer regulatory progress or a valuation pullback. Maintain WAIT but lower conviction from 2.5 to 2.0 and adjust bull scenario probability downward from 20% to 15%, with bear probability rising from 25% to 30%.